Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+advanced or metastatic breast cancer(MBC)

Rob Riemsma*, Carol A. Forbes, Mayur M. Amonkar, Konstantinos Lykopoulos, Jose R. Diaz, Jos Kleijnen, Daniel W. Rea

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1263-1279
JournalCurrent Medical Research and Opinion
Issue number8
Publication statusPublished - Aug 2012


  • Advanced or metastatic breast cancer
  • Aromatase inhibitor
  • First line treatment
  • HR
  • HER2+
  • Lapatinib

Cite this